Harbinger Health

Analyzes body fluids for cancer biomarkers to support early detection and ongoing disease monitoring.

Vetted listing

Testing

Consented intake · your records travel with you · nothing moves without your sign-off

Why Harbinger exists

Harbinger Health provides liquid biopsy testing, analyzing blood and other bodily fluids for biomarkers such as DNA, RNA, and proteins. The testing is aimed at early detection and at monitoring disease, including minimum residual disease. For patients, it is a source of biomarker information that can help guide treatment and track progression.

CLIA · 22D2262943CAP · 9868028A Flagship Pioneering companyNamed partners · Dana-Farber Cancer Institute, HCA Healthcare Sarah Cannon Cancer Network, GI Alliance

Prefer the source? Harbinger Health's own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Harbinger Health handles billing.

We don't have confirmed insurance details for Harbinger Health yet. Start a coverage check with your plan, or contact the provider directly.

Ask about this service

Answers grounded in Harbinger's details here. Educational only; your oncologist directs treatment.

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.